Functional consequences of mutations in the myosin heavy chain at sites implicated in familial hypertrophic cardiomyopathy

Trends in Cardiovascular Medicine

Volumn 12, Issue 8, 2002, Pages 348-354

  Lowey, Susan ^a,b  

^a UNIVERSITY OF VERMONT   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYOSIN HEAVY CHAIN;

FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; GENE MUTATION; HEART MUSCLE CELL; HUMAN; MYOFILAMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; HUMANS; MUTATION; MYOSIN HEAVY CHAINS; MYOSINS;

EID: 0036872230     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1050-1738(02)00181-0     Document Type: Review

References (33)

1. Barany M. ATPase activity of myosin correlated with speed of muscle shortening. J Gen Physiol. 50(Suppl):1967;197-218.
2. Bonne G., Carrier L., Richard P.et al. Familial hypertrophic cardiomyopathy. from mutations to functional defects Circ Res. 83:1998;580-593.
3. Bunn F.H. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 337:1997;762-769.
4. Cuda G., Fananapazir L., Epstein N.D., Sellers J.R. The in vitro motility activity of β-cardiac myosin depends on the nature of the β-myosin heavy chain gene mutation in hypertrophic cardiomyopathy. J Muscle Res Cell Motil. 18:1997;275-283.
5. Cuda G., Fananapazir L., Zhu W.-S.et al. Skeletal muscle expression and abnormal function of β-myosin in hypertrophic cardiomyopathy. J Clin Invest. 91:1993;2861-2865.
6. Dominguez R., Freyzon Y., Trybus K.M., Cohen C. Crystal structure of a vertebrate smooth muscle myosin motor domain and its complex with the essential light chain. visualization of the pre-power stroke state Cell. 94:1998;559-571.
7. -. Biochemistry. 34:1995;8960-8972.
8. Fujita H., Sugiura S., Monomura S.et al. Characterization of mutant myosins of Dictyostelium discoideum equivalent to human familial hypertrophic cardiomyopathy mutants. J Clin Invest. 99:1997;1010-1015.
9. Geeves M.A., Holmes K.C. Structural mechanism of muscle contraction. Annu Rev Biochem. 68:1999;687-728.
10. Geisterfer-Lowrance A.A., Christe M., Conner D.A.et al. A mouse model of familial hypertrophic cardiomyopathy. Science. 272:1996;731-734.
11. Geisterfer-Lowrance A.A., Kass S., Tanigawa G.et al. A molecular basis for familial hypertrophic cardiomyopathy. a β cardiac myosin heavy chain gene missense mutation Cell. 62:1990;999-1006.
12. Hoffman E., Kunkel L.M. Dystrophin abnormalities in Duchenne/Becker muscular dystrophy. Neuron. 2:1989;1019-1029.
13. Huxley H.E. The mechanism of muscle contraction. Science. 164:1969;1356-1366.
14. Marian A.J., Wu Y., Lim D.-S.et al. A transgenic rabbit model for human hypertrophic cardiomyopathy. J Clin Invest. 104:1999;1683-1692.
15. Marian A.J., Yu Q.-T., Mann D.L.et al. Expression of a mutation causing hypertrophic cardiomyopathy disrupts sarcomere assembly in adult feline cardiac myocytes. Circ Res. 77:1995;98-106.
16. McNally E.M., Kraft R., Bravo-Zehnder M.et al. Full length rat alpha and beta cardiac myosin heavy chain sequences. J Mol Biol. 210:1989;665-671.
17. Olson T.M., Doan T.P., Kishimoto N.Y.et al. Inherited and de novo mutations in the cardiac actin gene cause hypertrophic cardiomyopathy. J Mol Cell Cardiol. 32:2000;1687-1694.
18. Palmiter K.A., Tyska M.J., Haeberle J.R.et al. R403Q and L908V mutant β-cardiac myosin from patients with familial hypertrophy cardiomyopathy exhibit enhanced mechanical performance at the single molecule level. J Muscle Res Cell Motil. 21:2000;609-620.
19. Rayment I., Holden H.M., Sellers J.R.et al. Structural interpretation of the mutations in the β-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy. Proc Natl Acad Sci USA. 92:1995;3864-3868.
20. Rayment I., Holden H.M., Whittaker M.et al. Structure of the actin-myosin complex and its implications for muscle contraction. Science. 261:1993;58-65. a.
21. Rayment I., Rypniewski W.R., Schmidt-Base K.et al. Three-dimensional structure of myosin subfragment-1. a molecular motor Science. 261:1993;50-58. b.
22. Roopnarine O., Leinwand L.A. Functional analysis of myosin mutations that cause familial hypertrophic cardiomyopathy. Biophys J. 75:1998;3023-3030.
23. Sata M., Ikebe M. Functional analysis of the mutations in the human cardiac β-myosin that are responsible for familial hypertrophic cardiomyopathy. J Clin Invest. 98:1996;2866-2873.
24. Sweeney H.L., Straceski A.J., Leinwand L.A.et al. Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction. J Biol Chem. 269:1994;1603-1605.
25. Tardiff J.C., Hewett T.E., Factor S.M.et al. Expression of the β (slow)-isoform of MHC in the adult mouse heart causes dominant-negative functional effects. Am J Physiol Heart Circ Physiol. 278:2000;H412-H419.
26. Tyska M.J., Hayes E., Giewat M.et al. Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy. Circ Res. 86:2000;737-744.
27. VanBuren P., Harris D.E., Alpert N.R., Warshaw D.M. Cardiac V1 and V3 myosins differ in their hydrolytic and mechanical activities in vitro. Circ Res. 77:1995;439-444.
28. Vikstrom K.L., Leinwand L.L. Contractile protein mutations and heart disease. Curr Opin Cell Biol. 8:1996;97-105.
29. Volkmann N., Hanein D., Ouyang G.et al. Evidence for cleft closure in actomyosin upon ADP release. Nature Struct Biol. 7:2000;1147-1155.
30. Vybiral T., Deitiker P.R., Roberts R., Epstein H.F. Accumulation and assembly of myosin in hypertrophic cardiomyopathy with the 403 Arg to Gln β-myosin heavy chain mutation. Circ Res. 71:1992;1404-1409.
31. Warshaw D.M. The in vitro motility assay. a window into the myosin molecular motor News Physiol Sci. 11:1996;1-7.
32. Warshaw D.M., Desrosiers J.M., Work S.S., Trybus K.M. Smooth muscle myosin cross-bridge interactions modulate actin filament sliding velocity in vitro. J Cell Biol. 111:1990;453-463.
33. Yamashita H., Tyska M.J., Warshaw D.M.et al. Functional consequences of mutations in the smooth muscle myosin heavy chain at sites implicated in familial hypertrophic cardiomyopathy. J Biol Chem. 275:2000;28,045-28,052.